TScan Therapeutics is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. TCR-T therapy involves genetically reprogramming a patient's T cells with synthetic receptors designed to recognize and kill cancer cells expressing specific target antigens. TScan's lead program, TSC-101, targets AML and MDS patients undergoing allogeneic bone marrow transplants. After transplant, residual leukemia cells frequently cause relapse, the primary driver of mortality in this population. TSC-101 uses donor-derived T cells engineered to recognize HA-2, an antigen present on blood cells in patients with a specific genetic profile, selectively eliminating residual cancer cells while sparing healthy donor-derived cells repopulating the body. TScan is enrolling patients in a Phase 1 trial and plans to initiate a registrational trial in Q2 2026. The pipeline also includes TSC-102-A01 and TSC-102-A03, targeting CD45 across additional HLA types, with Phase 1 studies planned for the second half of 2026. TScan has paused its solid tumor program to focus on heme malignancies and is pivoting solid tumors to an in vivo engineering approach. TScan has no approved products and generates no product revenue. The company funds itself through equity raises and a collaboration with Amgen, which provided a $30M upfront payment to discover targets in Crohn's disease, with over $500M in potential milestones plus royalties.